In the Rizvi cohort, 206 and 34 NSCLC patients were treated with anti-PD-1/PD-L1 and anti-PD-1/PD-L1 plus anti-CTLA-4, respectively (Table 1). This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.